- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04002167
A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
November 22, 2023 updated by: Hadi Hosseini, Stanford University
A Novel Neuromonitoring Guided Cognitive Intervention for Targeted Enhancement of Working Memory
The proposed study is to test and validate a novel intervention that integrates computerized cognitive training with real-time neuromonitoring and neurofeedback to enhance working memory by probing the individualized neural systems underlying working memory.
We will test the proposed intervention on children with ADHD with working memory deficits.
The R61 proof-of-concept phase will assess the target engagement, effective dose and feasibility.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 11 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion criteria include:
- Age from 7 to 11 years
- Diagnosis and/or current symptoms of ADHD
- Full-scale Intelligence quotient (IQ) ≥80
- Behavior Rating Inventory of Executive Functions (BRIEF), Working Memory Scale t-score > 65
- Allowed comorbidities include oppositional defiant disorder, learning disabilities excluding dyslexia, and mild anxiety and/or depression.
Exclusion criteria:
- Presence of severe neurological or psychiatric disease other than those allowed under inclusion
- Sensory deficits that would preclude participation in assessments or imaging
- History of significant head trauma with loss of consciousness
- Contraindications to MRI (e.g. metal implants or claustrophobia)
- Enrollment in other intervention studies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Neurofeedback
The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
|
The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
|
|
Active Comparator: Cognitive Training
The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
|
The Cognitive training group will receive computerized working memory training with performance feedback.
|
|
No Intervention: Waitlist
Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Target Frontal-parietal Activity
Time Frame: baseline and 6 weeks
|
Change in activity in the target frontal-parietal network measured by functional near infrared spectroscopy (fNIRS) during an N-back working memory task.
A general linear model is applied to recorded signal and the beta coefficients from the model are extracted as a proxy for brain activity in fronto-pariteal network which subserves working memory function.
There is no established population mean for beta coefficient of brain activity.
Higher (lower) beta coefficients reflect higher (lower) activation in the target brain network.
A positive change indicates increased brain activity.
Increased frontal-parietal activity reflects better engagement of this brain network during working memory performance.
|
baseline and 6 weeks
|
|
Change in Working Memory Performance
Time Frame: baseline and 6 weeks
|
Accuracy in an N-back working memory task was calculated as the percentage of correct responses to target stimuli.
|
baseline and 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Behavior Rating Inventory of Executive Function (BRIEF), Working Memory T-score
Time Frame: baseline and 6 weeks
|
BRIEF assesses everyday behavior associated with specific domains of the executive functions.
BRIEF working memory T-score ranges from <30 to >100 with higher scores indicating larger impairment in working memory.
Lower T-scores on BRIEF indicates better working memory.
T-score of 50 indicates the population mean with a standard deviation of 10.
BRIEF working memory T-score of 65 and higher is indicative of deficits in working memory.
|
baseline and 6 weeks
|
|
Change in Wide Range Assessment of Memory and Learning 2 (WRAML-2), General Memory Index Score
Time Frame: baseline and 6 weeks
|
WRAML-2 assesses clinical issues in learning and memory functions.
WRAML-2 Working Memory Index score ranges from 50 to 150 with higher scores indicating better working memory performance
|
baseline and 6 weeks
|
|
Change in Conners 3rd Edition ADHD Index Score
Time Frame: baseline and 6 weeks
|
Conners 3 will be used to measure changes in clinical ADHD symptoms.
Conners 3 ADHD index score ranges from 0 to 100 with higher scores indicating elevated ADHD symptoms.
Conners 3 ADHD index score of higher than 65 is indicative of ADHD diagnosis.
|
baseline and 6 weeks
|
|
Change in Conners 3rd Edition Inattention T-score
Time Frame: baseline and 6 weeks
|
Conners 3 will be used to measure changes in clinical inattention symptoms.
Conners 3 inattention t-score ranges from <30 to >100 with higher scores indicating larger impairment in attention.
T-score of 50 indicates the population mean with a standard deviation of 10.
Inattention t-score of 65 and higher is indicative of deficits in attention.
|
baseline and 6 weeks
|
|
Change in Developmental NEuroPSYchological Assessment II (NEPSY-II) Composite Score
Time Frame: baseline and 6 weeks
|
NEPSY-II consists of a set of subtests measuring cognitive functions required for success in school.
The subtests include auditory attention & response, inhibition, word-list interference, and comprehension of instructions.
The composite scores were quantified by averaging the scores across sub-scales.
A positive change in composite score suggests increased ability in subtest domains.
The composite score below 8 suggest deficits.
The composite scores range from 0 to 20; lower scores correspond to more deficits, and higher scores correspond to more abilities.
|
baseline and 6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Parent Stress Index 4th Edition (PSI-IV)
Time Frame: baseline and 6 weeks
|
PSI-IV evaluates the magnitude of stress in the parent-child system
|
baseline and 6 weeks
|
|
Change in Continuous Performance Test (CPT) Accuracy
Time Frame: baseline and 6 weeks
|
CPT is standard test for measuring vigilance, sustained attention and inhibitory control.
|
baseline and 6 weeks
|
|
Change in California Verbal Learning Test - Children's Version (CVLT-C) Score
Time Frame: baseline and 6 weeks
|
CVLT-C test measures performance in learning and recalling verbal materials
|
baseline and 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Hadi Hosseini, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2019
Primary Completion (Actual)
August 26, 2022
Study Completion (Actual)
September 14, 2022
Study Registration Dates
First Submitted
June 24, 2019
First Submitted That Met QC Criteria
June 26, 2019
First Posted (Actual)
June 28, 2019
Study Record Updates
Last Update Posted (Estimated)
December 13, 2023
Last Update Submitted That Met QC Criteria
November 22, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 328066
- R61MH119289 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.